Literature DB >> 8224248

In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors.

V Breu1, B M Löffler, M Clozel.   

Abstract

Ro 46-2005 is a new synthetic non-peptide endothelin (ET) receptor antagonist. In binding experiments, Ro 46-2005 proved to be equipotent (IC50 200-500 nM) for inhibition of [125]ET-1 binding on the two known ET receptor subtypes (ETA and ETB). Scatchard analysis was consistent with a competitive binding mode. Ro 46-2005 also inhibited the functional consequences of ET-1 stimulation: the ET-1 induced release of arachidonic acid from rat mesangial cells was inhibited with an IC50 of 1.8 microM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224248     DOI: 10.1016/0014-5793(93)81713-a

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Characterization of [125I]-endothelin-1 and [125I]-BQ3020 binding to rat cerebellar endothelin receptors.

Authors:  P S Widdowson; C N Kirk
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 2.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

3.  [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Authors:  Michael Zimmermann; Carla Sabine Jung; Hartmut Vatter; Andreas Raabe; Volker Seifert
Journal:  Neurosurg Rev       Date:  2002-11-19       Impact factor: 3.042

Review 4.  The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction.

Authors:  Elizabeth A W Chan; Barbara Buckley; Aimen K Farraj; Leslie C Thompson
Journal:  Pharmacol Ther       Date:  2016-05-21       Impact factor: 12.310

5.  Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors.

Authors:  K W Buchan; C Alldus; C Christodoulou; K L Clark; C W Dykes; M J Sumner; D M Wallace; D G White; I S Watts
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

Review 6.  Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Authors:  G Noll; R R Wenzel; T F Lüscher
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.